Wall Street analysts have released their latest round of evaluations, highlighting key stock movements in upgrades, downgrades, and new coverage. This compilation offers investors a succinct overview of the most impactful research calls that could influence market dynamics.
Detailed Investment Outlook: Major Firm Adjustments and New Initiations
On Monday, July 13, 2026, a series of pivotal analyst calls from prominent financial institutions impacted several major corporations. JPMorgan notably elevated its rating for American Express to Overweight from Neutral, boosting its price target from $328 to $400. This revision reflects confidence in the company's resilient revenue streams, which are perceived as relatively defensive in the current market climate.
Concurrently, Truist upgraded Biogen from Hold to Buy, increasing its price target to $235 from $190. This decision comes ahead of crucial data presentations for BIIB080 at next week's AAIC conference and anticipated Phase 3 pipeline readouts for litifilimab in Q4. The firm's optimistic stance is fueled by expectations for groundbreaking Phase 2 data from Diranersen, suggesting a favorable risk/reward scenario for the pharmaceutical giant.
Jefferies upgraded Shopify to Buy from Hold, with a revised price target of $160, up from $140. This upgrade is predicated on third-party data indicating that Shopify's fiscal Q2 results are likely to surpass consensus estimates. Morgan Stanley also adjusted its rating for Keysight Technologies to Overweight from Equal Weight, with a price target increase to $400 from $350, viewing it as a prime beneficiary of AI investment expansion.
Adding to the upgrades, Wells Fargo moved Humana to Overweight from Equal Weight, significantly raising its price target from $227 to $502. This substantial adjustment is attributed to a reassessment of Medicare Advantage cost trends, suggesting a more positive outlook for the health insurer.
In contrast, BofA downgraded Papa John's to Underperform from Neutral, reducing its price target to $34 from $42. The downgrade follows the departure of the former CFO, raising concerns about the company's immediate turnaround prospects. Loop Capital downgraded Best Buy to Hold from Buy, maintaining an $82 price target, indicating a more cautious stance on the electronics retailer.
RBC Capital shifted Kymera Therapeutics to Sector Perform from Outperform, though it raised the price target slightly to $115 from $106. The firm acknowledges the potential of STAT6 degrader '621 as a significant treatment option and the company's attractiveness as an M&A target, but posits a more balanced risk/reward profile. Keefe Bruyette also downgraded Porch Group to Market Perform from Outperform, adjusting its price target to $16.25 from $13. This change reflects the stock's considerable rally over the past three months, leading to a more equilibrium risk/reward assessment. Piper Sandler moved Ameris Bancorp to Neutral from Overweight, setting a $96 price target, citing a recent stock rally and moderated expectations for share repurchases and mortgage recovery.
New coverage initiations included Benchmark's Buy rating for Disney with a $115 price target, emphasizing the company's long-term value in a diversified digital and physical ecosystem. Evercore ISI began coverage on Honeywell Aerospace with an In Line rating and a $250 price target, noting a solid outlook but limited upside at current valuation. JPMorgan resumed coverage of Alkermes with a Neutral rating and a $60 price target, highlighting its emerging role in the sleep disorder market. Guggenheim initiated BrightSpring Health with a Buy rating and an $81 price target, recognizing its strong position in home and community-based care. Lastly, B. Riley initiated coverage on Spruce Biosciences with a Buy rating and a $160 price target, pointing to an undervalued enterprise with significant potential from its Priority Review Voucher.
The financial market is a complex ecosystem, constantly re-evaluating company prospects. These analyst reports serve as vital compass points for investors, guiding their decisions by offering professional insights into the strengths and weaknesses of various corporations. It underscores the dynamic nature of stock valuations, where factors from leadership changes to clinical trial outcomes can swiftly alter investment attractiveness. For both seasoned and new investors, keeping abreast of these expert opinions is crucial for navigating the ever-shifting currents of the market.
